Under-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period

Eur J Prev Cardiol. 2022 Mar 30;29(4):e149-e152. doi: 10.1093/eurjpc/zwab096.
No abstract available

Keywords: Atrial fibrillation; COVID-19; Direct oral anticoagulants; SARS-CoV-2; Venous thromboembolism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / diagnosis
  • Atrial Fibrillation* / drug therapy
  • Atrial Fibrillation* / epidemiology
  • COVID-19*
  • Communicable Disease Control
  • Humans
  • Prescriptions
  • Venous Thromboembolism* / diagnosis
  • Venous Thromboembolism* / drug therapy
  • Venous Thromboembolism* / epidemiology

Substances

  • Anticoagulants